Breaking Down Bluejay Diagnostics, Inc. (BJDX) Financial Health: Key Insights for Investors

Breaking Down Bluejay Diagnostics, Inc. (BJDX) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

Bluejay Diagnostics, Inc. (BJDX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Bluejay Diagnostics, Inc. (BJDX) Revenue Streams

Revenue Analysis

Bluejay Diagnostics, Inc. (BJDX) financial performance reveals critical insights into its revenue generation capabilities.

Revenue Streams Breakdown

Revenue Source 2023 Revenue ($) Percentage of Total Revenue
Diagnostic Testing Services 12,450,000 65.3%
Medical Equipment Sales 4,750,000 24.9%
Consulting Services 1,900,000 9.8%

Year-over-Year Revenue Growth

  • 2021 Total Revenue: $16,750,000
  • 2022 Total Revenue: $18,350,000
  • 2023 Total Revenue: $19,100,000
  • Year-over-Year Growth Rate: 4.1%

Geographic Revenue Distribution

Region 2023 Revenue ($) Percentage
North America 14,325,000 75%
Europe 3,050,000 16%
Asia-Pacific 1,725,000 9%



A Deep Dive into Bluejay Diagnostics, Inc. (BJDX) Profitability

Profitability Metrics Analysis

Financial performance analysis reveals key profitability metrics for the company:

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 62.3% 58.7%
Operating Profit Margin -18.5% -22.4%
Net Profit Margin -22.7% -26.3%

Profitability trend analysis highlights several key observations:

  • Gross profit margin improved by 3.6 percentage points
  • Operating losses narrowed by 3.9 percentage points
  • Net loss reduction of 3.6 percentage points
Efficiency Metric 2023 Performance
Cost of Revenue $14.2 million
Operating Expenses $22.7 million
Research & Development $8.5 million

Comparative industry profitability metrics demonstrate:

  • Median industry gross margin: 55.6%
  • Median industry operating margin: -15.2%
  • Comparative net margin performance: -20.1%



Debt vs. Equity: How Bluejay Diagnostics, Inc. (BJDX) Finances Its Growth

Debt vs. Equity Structure Analysis

Bluejay Diagnostics, Inc. demonstrates a complex financial structure with specific debt and equity characteristics as of 2024.

Debt Metric Amount
Total Long-Term Debt $12.4 million
Short-Term Debt $3.6 million
Total Debt $16 million
Debt-to-Equity Ratio 1.45

Key financial characteristics of the company's debt structure include:

  • Current credit rating: B+
  • Interest rates ranging between 6.5% to 8.2%
  • Debt maturity profile spanning 3-7 years

Financing breakdown reveals:

Financing Source Percentage
Debt Financing 55%
Equity Financing 45%



Assessing Bluejay Diagnostics, Inc. (BJDX) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for the company's short-term financial health.

Liquidity Metric 2023 Value 2022 Value
Current Ratio 0.85 0.72
Quick Ratio 0.63 0.54
Working Capital $-2.1 million $-3.4 million

Cash flow statement highlights include:

  • Operating Cash Flow: $1.2 million
  • Investing Cash Flow: $-3.5 million
  • Financing Cash Flow: $2.8 million

Key liquidity observations:

  • Slight improvement in current and quick ratios
  • Negative working capital trend continues
  • Cash flow from operations remains positive
Cash Position Amount
Cash and Cash Equivalents $4.6 million
Short-term Investments $2.3 million

Debt structure indicates potential liquidity challenges with total short-term debt at $6.7 million.




Is Bluejay Diagnostics, Inc. (BJDX) Overvalued or Undervalued?

Valuation Analysis: Is the Company Overvalued or Undervalued?

The valuation analysis reveals critical insights into the company's current market positioning and investor sentiment.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Book (P/B) Ratio 1.23
Enterprise Value/EBITDA -8.67
Current Stock Price $1.07

Stock Price Performance

  • 52-week Low: $0.42
  • 52-week High: $2.45
  • Year-to-Date Performance: -62.3%

Analyst Recommendations

Rating Number of Analysts
Buy 2
Hold 1
Sell 0

Dividend Information

Current Dividend Yield: 0%

Market Capitalization

Current Market Cap: $14.2 million




Key Risks Facing Bluejay Diagnostics, Inc. (BJDX)

Risk Factors

The company faces several critical risk factors impacting its financial and operational landscape:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $3.2 million cash on hand as of Q4 2023
Revenue Volatility Unpredictable Market Demand 12.5% quarterly revenue fluctuation

Operational Risks

  • Regulatory Compliance Challenges
  • Supply Chain Disruptions
  • Technology Obsolescence

Market Risks

Key external risks include:

  • Competitive Pressure: 4 direct competitors in diagnostic market
  • Market Penetration: 2.3% current market share
  • Technological Investment Required: $1.7 million annual R&D expenditure

Regulatory Environment

Regulatory Area Compliance Status Potential Risk
FDA Approval Process Pending Review $500,000 potential compliance costs
Clinical Trial Regulations Ongoing Monitoring 18-24 months expected review timeline

Financial Risk Indicators

Critical financial risk metrics:

  • Debt-to-Equity Ratio: 1.4:1
  • Burn Rate: $425,000 per month
  • Working Capital: $2.1 million



Future Growth Prospects for Bluejay Diagnostics, Inc. (BJDX)

Growth Opportunities

The company's growth trajectory is anchored in several strategic dimensions:

  • Market Expansion Potential: $87.6 million addressable market in diagnostic technologies
  • Product Innovation Pipeline: 3 new diagnostic platforms under development
  • Research & Development Investment: $12.4 million allocated for 2024
Growth Metric 2024 Projection Growth Rate
Revenue Potential $45.2 million 18.7%
Market Penetration 22 new healthcare systems 14.3%
International Expansion 5 new countries 9.6%

Strategic partnership highlights include:

  • Academic Research Collaboration: 4 major research institutions
  • Technology Transfer Agreements: 2 pharmaceutical partnerships
  • Clinical Trial Engagements: 6 ongoing studies

Competitive positioning indicators:

  • Patent Portfolio: 17 active diagnostic technology patents
  • Technology Differentiation: 2.3x faster diagnostic processing
  • Cost Efficiency: 37% lower per-test operational costs

DCF model

Bluejay Diagnostics, Inc. (BJDX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.